Targeting inflammation in the treatment of type 2 diabetes

Donath, M. Y.. (2013) Targeting inflammation in the treatment of type 2 diabetes. Diabetes, obesity and metabolism, Vol. 15, suppl. 3. pp. 193-196.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6338612

Downloads: Statistics Overview


Islets of patients with type 2 diabetes display the typical features of an inflammatory process characterized by the presence of cytokines, chemokines, immune cell infiltration, impaired function and tissue destruction with fibrotic areas. Functional studies have shown that targeting inflammation may improve insulin secretion and sensitivity. In particular clinical proof of concept studies using modulators of the interleukin-1beta (IL-1beta)-nuclear factor--kappaB (NF-kappaB) pathway demonstrated the role of the innate immune system in type 2 diabetes. This programme has now entered the phase 3 of clinical development. Other targets such as tumour necrosis factor alpha (TNFalpha) may be equally important but have been neglected based on poorly designed studies. In this article we discuss the mechanisms of islet inflammation in type 2 diabetes and review the opportunity of clinical translation.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Diabetes Research (Donath)
UniBasel Contributors:Donath, Marc
Item Type:Article, refereed
Article Subtype:Research Article
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:10 Apr 2015 09:13
Deposited On:10 Apr 2015 09:13

Repository Staff Only: item control page